BioTheus acquisition by BioNTech to boost its Nantong biotech base

Biotech company BioTheus recently announced that it had reached an equity acquisition agreement with BioNTech, a globally renowned pharmaceutical company from Germany.

Under the terms of the agreement, BioNTech will acquire 100 percent of BioTheus's issued shares for an upfront payment of $800 million.

BioTheus's Nantong branch plays a critical role in the company's antibody drug development chain, operating a 61,000-square-meter production facility in the Nantong Economic and Technological Development Area (NETDA) that meets international standards.

Since its early days, BioTheus has seen steady growth and positive economic returns from the facility. Following the acquisition, the Nantong base will continue its operations, aiming to become a premier biopharmaceutical production hub.

With this acquisition, BioTheus's Nantong site will become BioNTech's only production base in China, contributing to the global supply and production of BioNTech's products. 

The partnership with BioNTech is expected to bring high-quality resources, advanced technology, and management expertise to the Nantong facility, accelerating its growth and expansion as a leading production center in biopharmaceuticals.

A night view of Nantong Economic and Technological Development Area. [Photo/WeChat account: gh_78ba52d6e1ed]